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Whilst there is an extensive body of preclinical nanomedicine research, translation to clinical settings has
been slow. Here we present a novel approach to the targeted nanoparticle (NP) concept: utilizing both a
novel targeting ligand, VNAR (Variable New Antigen Receptor), a shark-derived single chain binding
domain, and an under-investigated target in delta-like ligand 4 (DLL4). We describe the development of
an anti-DLL4 VNAR and the site-specific conjugation of this to poly(lactic-co-glycolic) acid PEGylated
NPs using surface maleimide functional groups. These nanoconjugates were shown to specifically bind
DLL4 with high affinity and were preferentially internalized by DLL4-expressing pancreatic cancer cell
lines and endothelial cells. Furthermore, a distinct anti-angiogenic effect endowed by the anti-DLL4
VNAR was evident in in vitro tubulogenic assays. Taken together these findings highlight the potential of
anti-DLL4 targeted polymeric NPs as a novel therapeutic approach in pancreatic cancer.
Introduction
Over the last 15–20 years nanoformulations for both thera-
peutic and diagnostic applications have been increasingly
investigated. Such delivery systems have the potential to maxi-
mise drug delivery to the requisite site, minimising off-target
toxicities.1 As potential chemotherapeutics, NPs may passively
target tumours through the enhanced permeability and reten-
tion (EPR) effect, wherein leaky hypervasculature permits the
extravasation of the nanosystem into tumour tissue and poor
lymphatic clearance minimises removal.2–4
NPs can be further tailored by functionalizing their exterior
with targeting ligands. Such ligands can be used to target an
encapsulated therapeutic payload to the requisite site whilst
through interaction with receptors and other molecules, target-
ing moieties can themselves impart biological function.5–9
One potential targeting approach that has not yet been ade-
quately investigated is that of using Variable New Antigen
Receptors (VNARs).
VNARs are the smallest (11 kDa) naturally occurring inde-
pendent binding domains in the vertebrate kingdom, playing
an integral role in the adaptive immune system of cartilagi-
nous fish.10–12 Structurally, their characteristic protruding
paratopes result in “canyon-binders”, predisposed to access
epitopes normally inaccessible to conventional biologics. This
enables the generation of ligands possessing high binding
efficacy and specificity.13–18 Furthermore, scaled VNAR
expression can be achieved cost-efficiently in non-mammalian
systems whilst their inherent stability makes them ideal for
chemically controlled orientated conjugation to NPs to provide
an efficient display of binding paratopes.
In this work a VNAR against Delta-like ligand 4 (DLL4) is
conjugated to therapeutic NPs in order to target their action to
DLL4-overexpressing tumours. DLL4 is a haploinsufficient
Notch1 ligand essential for embryonic vascular development
and arteriogenesis.19,20 Its specific role appears to be in the
selection of tip cells during angiogenesis, resulting in appro-
priately-branched vasculature.21,22 In vascular endothelial cells
hypoxia stimulates the production of VEGF-A23 which sub-
sequently increases expression of DLL4 through binding to
VEGFR2. Increased DLL4-Notch1 signalling then participates
in the appropriate spatial selection of endothelial tip cells.24
Structurally, DLL4 is a single-pass transmembrane protein,25
befitting its role in Notch signalling requiring cell–cell contact.
While DLL4 expression is very low in normal adult endo-
thelium, its overexpression has been observed in the tumour-
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associated endothelium of several cancers including bladder,
breast, colon, kidney and brain, while expression is much
lower or absent in nearby normal vasculature.26–30 DLL4 over-
expression is also observed in pancreatic ductal adeno-
carcinoma (PDAC), notably not just in tumour-associated vas-
culature but also in tumour cells themselves.
Immunohistochemical staining of patient samples indicates
>50% of PDAC samples have high DLL4 expression, falling to
approximately 20% in peritumoural tissues.32,34 This over-
expression of DLL4 in the tumour bulk and vasculature pre-
sents an opportunity for selective localisation of DLL4-binding
NPs, and any associated cargo, at the tumour site. High DLL4
expression in PDAC correlates with poor prognosis31–34
suggesting a pro-carcinogenic role. DLL4 blockade is found to
induce excessive sprouting of vasculature and to inhibit
tumour growth,35,36 while not causing the gastrointestinal tox-
icity observed with other Notch pathway inhibitors.37,38 DLL4
expression is also a marker of cancer stem cells (CSCs).
Preclinically, DLL4 blockade reduces EMT and the number of
CSCs,36,39 suggesting potential effects on PDAC recurrence and
metastatic ability. As such DLL4 is an exciting target for NP
therapies in PDAC, with potential therapeutic effects beyond
simply enhancing selective NP localization.
Hard-to-treat cancers such as PDAC have a five-year survival
rate of less than 4%; a shocking statistic that has remained vir-
tually unchanged since the 1970s. Therefore new therapeutic
strategies, such as DLL4 inhibition, are urgently required.
Given the potential of using VNARs as NP targeting moieties
we herein describe the formulation and assessment of a poly-
meric NP targeted against DLL4. Following determination of
the physical characteristics of the NP system, the ability of the
conjugated VNAR to bind recombinant DLL4 protein was
assessed in an array of assays. Subsequently, the functionality
of the VNAR-NP conjugate was assessed using in vitro cell
based assays.
Results and discussion
Isolation and functional characterization of DLL4-specific
VNAR E4-Fc
The DLL4 specific domain E4 was isolated from a synthetic
VNAR library using phage display technology. The library was
subjected to four rounds of solid phase selection and screened
for clones cross-reactive to both human and murine DLL4.
Binding clones were converted to an Fc format.17 VNAR E4-Fc
was chosen as a preferred lead due to an exquisite selectivity
for human and murine DLL4 over the closely related ligand
DLL1 (both human and murine), when assessed by ELISA
(Fig. 1A).
The extracellular domain of human DLL4 is a single pass
transmembrane protein containing 8 EGF repeats and a single
DSL region. The Genentech clinical benchmark mAb,
YW26.82, is known to bind an epitope within EGF like repeat
number 2.35 In order to narrow down the binding region
(epitope) of VNAR E4-Fc and determine whether it was similar
to that of YW26.82, a truncated version of human DLL4 was
expressed containing only the DSL and EGF repeats 1–3.
Binding of VNAR E4 and mAb YW26.82 to the truncated DLL4
protein was assessed by ELISA (Fig. 1B). YW26.82 binds the
truncated version as expected however, VNAR E4-Fc did not
bind within this region, indicating an epitope distinct from
YW26.82. This result also suggests that VNAR E4-Fc may bind
a more membrane proximal epitope. This is likely to be the
case as a result of both the smaller size of VNARs (∼11 kDa in
comparison to ∼150 kDa for a mAb) and their diverse range of
paratope topologies, which enable them to bind hidden or
cryptic epitopes, inaccessible to conventional antibodies. The
predisposition of VNARs to bind epitopes which are more
membrane proximal has been reported previously for a VNAR
that recognizes the ROR1 protein.40
Blockade of DLL4-Notch activity is known to induce hyper-
sprouting (branching) through the stimulation and differen-
tiation of an increased number of tip cells, leading to local
regions of hypoxia and non-productive angiogenesis. Aberrant
sprouting in a cancer setting therefore leads to increased
vessel density, tumour hypoxia and attenuated tumour
growth.35,41 Given that the data indicated that VNAR E4 bound
DLL4 through a distinct epitope to YW26.82, it was important
to determine whether this would still translate into an altered
sprouting phenotype. DLL4 blockade was assessed over a
period of 7 days in a HUVEC fibrin bead-sprouting assay, and
activity again compared with the clinical benchmark mAb
YW26.82. Representative images from each treatment are
shown in Fig. 2A. As previously reported, inhibition of the
DLL4-Notch pathway by YW26.82 resulted in a hyper sprouting
phenotype with multiple branch points on each sprout.35
Interestingly, treatment with VNAR E4-Fc resulted in an
Fig. 1 Binding specificity and selectivity of VNAR E4-Fc. Binding ELISAs
of (A) VNAR E4-Fc to human and murine DLL4 and the closely related
ligand DLL1 and (B) binding of the VNAR E4-Fc and YW26.82 mAb to a
truncated version of DLL4 displaying only DSL and EGF repeats 1–3.
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alternative sprouting phenotype with a reduced number of
sprouts each with a noticeably thicker lumen (Fig. 2A). The
number of branch points per bead were counted for each treat-
ment (Fig. 2B). The addition of YW26.82 to HUVEC cells led to
a significantly increased number of sprouts and branch
points, and the converse was true for VNAR E4-Fc, further rein-
forcing the argument that DLL4 blockade by VNAR E4-Fc is via
a novel epitope and/or mechanism.
Synthesis and characterization of VNAR-conjugated PLGA-PEG
NPs
As an alternative to utilizing a Fc-fusion protein to increase
VNAR binding avidity, conjugation to polymeric NPs was pro-
posed as an approach to enhance paratope display. We have
previously shown that using site-selective conjugation chem-
istries, formulations possessing high binding affinities can be
generated.42 Using a similar oil-in-water single emulsion evap-
oration approach, we successfully generated NPs incorporating
a PEGylated stealth coat and a maleimide functionality to
facilitate downstream site-selective conjugation to a free
c-terminal cysteine engineered into the VNAR fragments. Upon
assessment by DLS, these NPs were found to be approximately
200 nm in diameter with a slightly negative zeta potential of
−3 mV in PBS (Fig. 3A). Furthermore, the low polydispersity
(0.1) suggested that a uniform monodisperse population of
NPs had been generated by this strategy. The size and polydis-
persity parameters were further confirmed by NP tracking ana-
lysis (NTA) and scanning electron microscopy (SEM) (Fig. 3B
and C). The stability of this formulation was then assessed
over time. Isolated NPs were stored at a range of temperatures
(−80, −20, 4, room temperature and 37 °C), before being resus-
pended in PBS and reanalyzed by DLS, revealing that physical
characteristics remained largely unaltered (Fig. S1A–C†).
Evaluation of VNAR conjugated PLGA NPs binding to
recombinant DLL4
To facilitate the conjugation of the anti-DLL4 VNAR, E4, to the
maleimide moieties on the NP, the purified E4 VNAR was incu-
bated with the NPs under gentle agitation for 2 h, allowing an
80% conjugation efficiency, equating to 8 μg protein per mg
polymer formulation. As a control, a naive control VNAR, 2V,
was also conjugated to the NPs. Conjugation levels between
the two VNAR clones were noted to be comparable with both
conjugated NPs also possessing similar physicochemical
characteristics (Fig. 4A).
Analysis of VNAR-NP binding to DLL4 was initially con-
firmed by fluorescence-linked immunosorbent assay (FLISA),
using microtiter plates coated with DLL4-Fc protein. In these
experiments, the incorporation of rhodamine 6G in the NP
afforded fluorescent measurement of NP binding. For E4 con-
jugated NPs specific binding to DLL4-Fc was significantly
increased over that observed with the isotype control. 2V
isotype control nanoconjugate binding response was found to
be comparable to that of the nude, unconjugated NP (Fig. 4B).
To further assess the ability of the E4 VNAR-NP to recognize
DLL4, SPR analysis was carried out using DLL4-Fc protein
immobilized onto a carboxymethylated dextran chip. Samples
were allowed to flow over the chip for 15 s with a flow rate of
Fig. 2 DLL4 blockade by VNAR E4-Fc results in an alternative sprouting
phenotype. (A) HUVEC coated beads in a fibrin matrix were cultured for
7 days in media only (no treatment) or supplemented with 250 nM VNAR
E4-Fc or mAb YW26.82. The branch points of each sprout are indicated
by a star. Representative images under phase contrast and confocal
microscopy post F-actin staining are shown. (B) The number of branch
points per bead were counted and a total of 10 beads were analysed per
treatment (n = 3).
Fig. 3 Physical characterisation of PLGA-PEG-Mal polymeric NPs.
PLGA-PEG-Mal polymeric NPs were formed using a single emulsion–
solvent evaporation approach. The resulting nanostructures were phys-
ically assessed to ascertain their size and morphology by (A) DLS, (B)
NTA and (C) SEM.
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20 μL min−1. Chip regeneration was conducted between each
sample through the addition of sodium hydroxide solution
(25 mM–50 mM) at 20 μL min−1 for 15 s. Using equalized
amounts of NPs, we first demonstrated that binding of the
nude control NPs to the immobilized DLL4 protein was negli-
gible, whereas the E4 VNAR conjugated NPs showed markedly
enhanced binding. To ensure that we were not simply measur-
ing binding of free VNAR aggregates in our formulations, we
also prepared conjugation controls wherein the VNAR was sub-
jected to the same coupling and washing procedure in the
absence of NPs. The lack of response in these samples con-
firmed that the binding observed with the VNAR-NPs was
dependent on VNAR association with the NP, highlighting the
success of the maleimide-cysteine conjugation approach
(Fig. 4C and D).
The engineered C-terminal cysteine of the VNAR is expected
to be the most amenable residue to electrophile conjugation.
To highlight the advantageous nature of this site-specific coup-
ling approach we compared it to conventional NHS-ester chem-
istry that has been widely employed during the construction of
targeted nanoparticles to date. In the latter approach, conju-
gation to the NP occurs randomly at lysine residues throughout
the VNAR structure. Whilst the coupling efficiency of the
VNAR to the NP was similar using both chemistries (Fig. 5A),
vastly superior antigen binding was observed with the male-
imide chemistry. DLL4 binding, was noted to be ∼6.5 times
greater 30 s after sample addition for PLGA-PEG-Mal-E4 NPs
compared to PLGA-PEG-NHS-E4 NPs, as determined by SPR,
with similar findings observed using the FLISA approach
(Fig. 5B–D). This highlights that the site-specific nature of the
maleimide conjugation approach plays a critical role in
antigen binding; indicating improved paratope accessibility
due to controlled orientation of VNAR fragments on the NP
surface.
To rule out the possibility that the E4 VNAR was simply
adsorbed to the PLGA NP and not covalently attached, we then
Fig. 4 E4 (anti-DLL4) conjugated NPs bind specifically to recombinant DLL4 (A) size and PDI of E4 and 2V (isotype) conjugated PLGA-PEG-Mal NPs
and amount of conjugated VNAR as measured by DLS and mBCA respectively. (B) FLISA assessment of DLL4 binding by nude, E4- and 2V-conjugated
NPs. Assay performed in triplicate and data presented as mean of three independent experiments. Statistical significance was established by two-
way ANOVA and Tukey’s post-hoc test (****p ≤ 0.0001). (C) PLGA-PEG-Mal polymeric NPs were incubated with anti-DLL4 clone E4 VNAR. Post-
incubation, the ability of the NPs to bind DLL4 was determined by SPR. Data presented as representative SPR binding sensorgram and (D), corres-
ponding details for relative binding response.
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explored the binding characteristics of NPs employing
different proportions of the maleimide functionalized
PLGA-PEG-Mal copolymer. Incubations with these varying for-
mulations revealed that incorporation of increasing amounts
of the maleimide functionalized copolymer yielded increasing
binding; importantly, when 0% of the PLGA-PEG-Mal was used
in the formulation, binding of the NP to the DLL4 coated
plates was directly comparable to controls (Fig. 5E). This
demonstrates that the binding of these NPs to DLL4 is depen-
dent on the site-specific, maleimide-cysteine conjugation of
the VNAR to the NPs.
To further illustrate the specificity of the binding inter-
action between the anti-DLL4 VNAR targeted NPs and their
cognate antigen, FLISA binding was assessed following block-
ing of the NP-bound VNAR paratope with free DLL4-Fc
(Fig. S2A†) or the plate-bound DLL4-Fc epitope with free anti-
DLL4 VNAR (Fig. S2B†). In both cases reduction in binding of
the anti-DLL4 NPs highlights the specificity of the interaction
between the targeted VNAR NP and its cognate antigen (DLL4).
In order to assess the suitability of the VNAR-NP conjugates
for use in a biological setting, antigen binding was assessed
via FLISA in biological media. Encouragingly, significantly
enhanced binding of VNAR-targeted NPs was maintained over
non-targeted nude and isotype control NPs (Fig. S3†).
Evaluation of anti-DLL4 NPs to target DLL4 positive tumour
cells
Having demonstrated the selective binding of the E4-conju-
gated NPs to DLL4, suitable cell models were sought for more
biologically relevant investigation of the behaviour of the anti-
DLL4 NPs.
While DLL4 is classically considered an endothelial ligand
it has been shown that its expression is not restricted to the
vasculature and is indeed found within the tumour bulk where
Fig. 5 Anti-DLL4 VNAR conjugation is maleimide dependent. Rhodamine 6G loaded PLGA-PEG-Mal and PLGA-PEG-NHS polymeric NPs were incu-
bated with anti-DLL4 clone E4 VNAR. Post-incubation, NPs were assessed (A) in terms of the success of the conjugation reaction, as determined by
mBCA. Rhodamine 6G loaded PLGA-PEG-NHS-E4 and PLGA-PEG-Mal-E4 NPs binding assessment via (B) FLISA method. Data expressed as mean ±
standard deviation (SD). Representative of three independent experiments. Statistical significance was established by two-way ANOVA and Tukey’s
post-hoc test (****p ≤ 0.0001). (C) Binding assessment of PLGA-PEG-Mal-E4 and PLGA-PEG-NHS-E4 NPs by SPR. Data presented as relative binding
response with (D), corresponding SPR binding sensorgram details. Representative of three independent experiments. (E) Rhodamine 6G-loaded
PLGA-PEG-Mal polymeric NPs possessing varying proportions of PLGA-PEG-Mal copolymer, were conjugated with anti-DLL4 clone E4 VNAR and
binding assessed by FLISA. Data expressed as mean ± standard deviation (SD). Representative of two independent experiments. Statistical signifi-
cance was established by two-way ANOVA and Tukey’s post-hoc test (**p ≤ 0.01; ****p ≤ 0.0001).
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its signalling through Notch1 seems to promote maintenance
of CSCs and EMT, for example.36,39,43 Therefore it is valuable
to look at the effects of E4-conjugated NPs on pancreatic
cancer cells (i.e., cancer cell lines) to ascertain if anti-DLL4
NPs may be of benefit in targeting to the tumour bulk.
Published data indicates that several PDAC cell lines.
Including MIA PaCa-243 and PANC-1,44 express DLL4.
As such, DLL4 expression was investigated in MIA PaCa-2 and
PANC-1 cells by western blot and flow cytometry and both were
found to be DLL4 positive (Fig. 6A–D). The uptake of rhodamine
6G VNAR-conjugated NPs was assessed by plate reader in MIA
PaCa-2 and PANC-1 cells (Fig. 6E and F). The small yet significant
enhancement in uptake of DLL4-targeted over isotype-control NPs
indicates a potential role for using the E4 VNAR-NP as a platform
for targeted drug delivery to the tumour bulk.
Evaluation of anti-DLL4 NPs to target and modulate the
tumour vasculature
In addition to delivering a therapeutic payload to the tumour
bulk it may also be advantageous to target the tumour vascula-
ture. Therefore the next series of studies assessed the inherent
functionality of the anti-DLL4 VNAR, when conjugated to the
NP surface, against endothelial cells. Given that DLL4 is classi-
cally expressed in the vascular endothelium, HUVECs were
therefore employed as a cell model. In agreement with the lit-
erature, synergistic upregulation of DLL4 was observed in
these cells upon co-stimulation with VEGF and FGF (Fig. 7A
and B).29 Internalization of rhodamine-loaded E4-conjugated
NPs was assessed in DLL4-positive HUVEC cells. NPs and cells
were incubated together for 30 min at 4 °C, an approach well
characterised to discriminate between NP absorption and
active uptake in vitro.45 Unbound NPs were then removed by
washing before 3 h incubation at 37 °C to enable the cellular
uptake of surface bound NPs. Greater uptake of the E4-functio-
nalized NPs when compared to the nude NPs highlights the
impact of the anti-DLL4 VNAR in facilitating increased NP
internalization in DLL4 expressing cells (Fig. 7C).
As a further illustration of NP targeting, we prepared our
NPs encapsulating the cytotoxic agent camptothecin (CPT)
(Fig. S4†) and incubated these with the stimulated HUVECs for
Fig. 6 Basal expression of DLL4 in PDAC cell lines correlates with enhanced uptake of anti-DLL4 VNAR conjugated PLGA-PEG-Mal NPs (A) western
blot of lysates of MIA PaCa-2 and PANC-1 cells (N = 4). (B–C) Representative histograms of cell fluorescence intensity for MIA PaCa-2 and PANC-1
cells either unstained or stained with YW26.82 and an anti-human PE-conjugated secondary antibody (D) mean fluorescence intensity measure-
ments (relative to unstained control). Significance assessed by unpaired t-test (ns p > 0.05) (N = 3) (E–F) uptake of fluorescent NPs into MIA PaCa-2
and PANC-1 cells respectively. Significance was assessed by two-way ANOVA and Tukey’s post-hoc test (****p < 0.0001).
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1 h at 4 °C, before washing and replacing with fresh media.
Cells were treated with either 0.1 mg mL−1 or 0.2 mg mL−1 NP
treatments, corresponding to 0.22 μg mL−1 or 0.44 μg mL−1
CPT respectively. Measurement of cell viability at 24 and 48 h
highlighted a significant decrease in cell viability for the
VNAR-targeted NPs over non-targeted (nude) controls (Fig. 7D
and E). By using anti-DLL4 VNARs as targeting agents for NPs
there is therefore an opportunity to enhance the efficacy of
chemotherapeutics within the tumour and its associated DLL4
positive neovasculature.
Given the endogenous function of DLL4 in angiogenesis it
would be expected that DLL4 blockade by VNAR NPs would
impact angiogenic signalling in the absence of any other thera-
peutic payload, we investigated the effect of E4-conjugated NPs
in a tubulogenesis assay using HUVECs. In addition to growth
factor stimulation, DLL4 expression is upregulated under
hypoxic conditions. This upregulation under hypoxia is in
accordance with previous observations in endothelial cells
showing HIF-1α mediated transcriptional induction under
hypoxia.46,47 Such conditions are frequently found in the
tumour microenvironment, and were therefore used here to
replicate physiologically relevant enhancement of DLL4
expression (Fig. 8A). Following treatment with E4-conjugated
NPs there was a marked difference in HUVEC tube phenotype
(Fig. 8B and C). Quantification revealed no significant difference in
branching interval between E4 NP treatments at 100 and 500 nM
of NP-bound VNAR, indicating that anti-DLL4 effect of the E4 NPs
was saturating under the assay conditions at 100 nM. Free E4
VNAR was also compared to NP bound VNAR at 100 nM (Fig. 8D
and E). NP-bound VNAR decreased total mesh area significantly
more than free VNAR, which may be due to the avidity effect of the
multivalent NP versus the monovalent free VNAR. This change in
HUVEC phenotype was similar to that observed following treat-
ment with E4-Fc (Fig. 2). Again nascent branches did not extend/
continue to grow.
This effect may be justified by the VNAR ligand used here.
As previously shown, E4 appears to bind an epitope distinct
from that of the mAb YW26.82. The unique constrained struc-
ture of VNARs are more able to bind membrane proximal epi-
topes, inaccessible to conventional antibodies. This may
impart distinct conformational and functional changes upon
the cognate antigen. Further structural analysis is required to
fully elucidate the nature of the binding interaction between
E4 and DLL4. However, the impact on tubulogenesis seen
here, with inhibition of tube network formation observed fol-
lowing treatment with E4-NP, appears an exciting anti-angio-
genic approach. Conjugation of VNARs to NP surfaces has the
potential to broaden their therapeutic applications.
Fig. 7 Anti-DLL4 conjugated vNAR NPs enhance payload delivery to DLL4 expressing endothelial cells (A) HUVECs were treated with FGF and/or
VEGF for 24 h. Following treatment, cells were lysed and DLL4 expression validated by western blot. α-Tubulin was used as a loading control. (B)
Densitometry quantification of western blot DLL4 expression levels. (C) HUVEC cells (pre-stimulated with FGF and VEGF) were treated with either
rhodamine 6G loaded PLGA-PEG-Mal or PLGA-PEG-Mal-E4 NPs for 3 h, then washed, fixed and nuclear regions stained with DAPI. Cells were sub-
sequently imaged by confocal microscopy to assess formulation uptake. Three representative images per treatment group are shown. Scale bars =
10 μm. (D) HUVEC cells stimulated with VEGF/FGF were treated with CPT-loaded NPs for 1 h at 4 °C and cell viability was assessed 24 h and (E) 48 h
post treatment via CellTiter-Glo®. Cells were treated with either 0.1 mg mL−1 or 0.2 mg mL−1 NP treatments, corresponding to 0.22 μg mL−1 or
0.44 μg mL−1 CPT respectively. Representative of two independent experiments. Statistical significance was established by one-way ANOVA and
Tukey’s post-hoc test (*p ≤ 0.05; **p ≤ 0.01).
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Fig. 8 HUVEC tube morphology is altered upon treatment with anti-DLL4 VNAR conjugated NPs (A) Representative DLL4 western blot of lysates
derived from HUVECs cultured under varying oxygen conditions (5, 10 or 21% oxygen), β-actin used as loading control (B) quantification of total
mesh area from the below phase contrast images using Angiogenesis Analyzer FIJI plugin. Data pooled from 3 independent experiments and nor-
malized to untreated control. Statistical significance determined by two-way ANOVA (**p < 0.01, ****p < 0.0001). (C) Representative 10× phase-con-
trast images of HUVECs taken 6 hours after seeding with no treatment (untreated), E4 NPs (100 or 500 nM of NP-bound VNAR) or a matched
polymer concentration of nude NP. (D) Quantification of total mesh area from the below phase contrast images using Angiogenesis Analyzer FIJI
plugin. Data pooled from 3 independent experiments and normalized to untreated control. Statistical significance determined by two-way ANOVA
(****p < 0.0001). (E) Representative 10× phase-contrast images of HUVECs taken 6 hours after seeding with no treatment (untreated), E4 NPs (100
nM of NP-bound VNAR) or free E4 (100 nM).
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Conclusions
In summary we have demonstrated the potential application of
anti-DLL4 targeted NPs as therapeutics in pancreatic cancer.
Not only do these permit targeted delivery of nano-encapsu-
lated cargo to the tumour bulk, but they also inhibit angio-
genic DLL4-Notch1 signalling in models of the tumour vascu-
lature. This inhibition may be via the recognition, by the E4
VNAR, of a membrane proximal epitope that delivers a novel
inhibitory phenotypic change to growing cells, that in turn
could translate into enhanced therapeutic potency in vivo.
Whilst in vivomodels are now clearly required to fully elucidate
the potential of these NPs, they display promise particularly
when one considers the current dearth of treatment options
for life-shortening and aggressive solid-tumours such as those
found in pancreatic cancer.
Experimental
VNAR phage display library screening
VNAR E4 was isolated from a synthetic VNAR library contain-
ing 100 billion unique clones. Four rounds of solid phase,
phage display antigen selections were carried out as described
previously18 using MaxiSorp immunotubes (Nunc) coated with
10–4 µg ml−1 rhDLL4 (recombinant human) in PBS pH 7.4.
Outputs from each selection round were screened for speci-
ficity to human and murine DLL4 (1 µg ml−1 in PBS coating
concentration) by monoclonal phage and periplasmic extract
ELISAs. Phage binders were detected using HRP-conjugated
anti-M13 antibody (Stratech Scientific), and periplasmic
protein was detected using an HRP-conjugated anti-His anti-
body (Sigma-Aldrich).
VNAR E4 ACA version design, expression and purification
Full details have been detailed previously.42 An Alanine-
Cysteine-Alanine (ACA) motif was inserted in the C-terminal
region of VNAR E4 to facilitate site-specific NP conjugation. E4
ACA was cloned into the pIMS147 prokaryotic expression
vector and solubly expressed in E. coli TG1 following 1 mM
IPTG induction for 4 h at 30 °C, 250 rpm. E4 VNAR protein
was released after osmotic shock (20% w/v sucrose, 100 mM
Tris HCl pH7.6, 5 mM EDTA). His-tagged VNAR E4 was puri-
fied from the supernatant using Ni2+ IMAC resin and collected
in a chromatography column. Bound protein was washed with
1×PBS containing 10 mM Imidazole and eluted with 10 ml of
250 mM Imidazole, pH 8. Post batch IMAC purification, VNAR
E4 was subject to Anion Exchange chromatography. The frac-
tions containing VNAR E4 ACA were pooled and buffer
exchanged to 1×PBS, pH 7.4. Protein concentration was deter-
mined using the A280 spectrophotometer.
HUVEC fibrin bead sprouting assay
Fibrin gel angiogenesis assays were performed in a 24 well
optical plate as described previously.48 In brief, Cytodex
3 microcarrier beads (Amersham) were coated with HUVEC
cells at a concentration of 400 cells per bead for 4 hours at
37 °C and allowed to adhere overnight. Approximately 250
HUVEC coated beads per well were embedded in 2 mg ml−1
fibrin gel and catalyzed by the addition of 0.625 U ml−1 throm-
bin (Sigma-Aldrich, UK). NHLF (20 000 cells per well) were
seeded on top of each clot in EGM-2 medium supplemented
with the indicated angiogenesis inhibitor (250 nM VNAR E4-Fc
and YW26.83 benchmark mAb). The medium plus treatments
were refreshed every other day and the experiment terminated
at day 7 with the addition of 2% paraformaldehyde (PFA), for
1 h at 37 °C, followed by overnight incubation at room temp-
erature. Assays were quantified using phase-contrast
microscopy or confocal fluorescent microscopy after staining
for polymeric F-actin.
NP formulation
NPs were synthesized via a standard single emulsion evapor-
ation methodology. Briefly, PLGA 502H (15 mg) and
PLGA-PEG-Mal (5 mg) (or PLGA-PEG-NHS (5 mg)) were dis-
solved in 1 ml of dichloromethane and added dropwise via a
25G needle into an aqueous phase (7 ml) comprised of 2.5%
(w/v) polyvinyl alcohol in 2-(N-morpholino)ethanesulfonic acid
(MES) buffer (pH 5). Emulsion formation was instigated
through pulsed sonication for 90 seconds on ice. The resulting
emulsion was then stirred overnight to permit solvent evapor-
ation. Three sequential centrifugation wash steps were then
performed at 20 000g in PBS for a total of 60 min. The final NP
pellet was re-suspended as required in PBS.
1% (w/w) rhodamine 6G (Sigma-Aldrich, UK) was added
into the organic phase in order to produce fluorescently
labeled NPs for use in binding assays. Camptothecin (CPT)
loaded NPs were formulated via the addition of CPT 0.50%
(w/w). Briefly, for each 20 mg polymeric NP batch, CPT (10 μL
of a 10 mg mL−1 stock solution in DMSO) was added to the
DCM organic phase and mixed. This solution was then
injected into the aqueous phase as detailed above. Loaded
nanoparticles were purified via three sequential centrifugation
wash steps performed at 20 000g in PBS for a total of 60 min at
4 °C.
NP functionalization
VNAR was conjugated to the exterior of the PLGA-PEG-Mal NP
via the formation of a stable thioether bond. Briefly, 1% (w/w)
VNAR was added to the NPs (1 mg) and gently agitated for 2 h
at room temperature. After the conjugation reaction time had
elapsed, unbound VNAR was removed via centrifugation at
16 900g for 20 min at 4 °C. NPs were then collected and re-sus-
pended as required.
Success of NP functionalization was determined by micro-
bicinchoninic acid protein assay (micro BCA Protein Assay Kit,
Thermo Scientific Pierce, UK) as per manufacturer’s direc-
tions. Conjugated VNAR was quantified via comparison to
standards comprised of known concentrations of VNAR added
to nude NPs.
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NP formulation assessment
Post-formulation NPs were assessed in terms of size (mean
particle size Zave), polydispersity index (PDI) and zeta poten-
tial (NanoBrook Omni, Brookhaven Instruments Corporation,
US). Measurements were conducted, in triplicate, with NPs
resuspended at 0.1 mg ml−1 in deionised water. Additional
size analysis of unconjugated NPs was performed using NP
tracking analysis (NTA, Malvern NS300). In order to assess the
stability of the formulation, pelleted NPs were stored in a
variety of conditions (−80, −20, 4, room temperature and
37 °C), before being resuspended in PBS and reanalyzed by
DLS at predetermined intervals over the course of 28 days.
Scanning electron microscopy
NPs suspended in water (5 mg ml−1) were added to double-
sided copper tape, fixed to an aluminium stub and allowed to
dry. NPs were then sputter coated with gold and imaged using
an FEI Quanta 250 FEG – Environmental Scanning Electron
Microscope (E-SEM).
Surface plasmon resonance
NP binding was assessed via Surface Plasmon Resonance
(SPR). All experiments were conducted at 25 °C on a Biacore Q
instrument. HBS-EP running buffer (GE Healthcare) was also
used throughout. A carboxymethylated dextran CM5 sensor
chip (GE healthcare) was initially activated with 0.4 M EDC
and 0.1 M NHS enabling chip functionalisation with 20 μg
ml−1 recombinant human DLL4 Fc chimera protein (Sino
Biological) via carbodiimide chemistry. DLL4 Fc was prepared
in a 10 mM sodium acetate buffer at pH 4.5. Following Fc
addition 1 M ethanolamine hydrochloride (pH 8.5) was used
to quench remaining NHS esters. Chip activation, functionali-
zation and subsequent quenching solutions were permitted
7 min chip contact time with flow rate maintained at 10 μl
min−1. NPs, suspended in HBS-EP running buffer were added
at the requisite concentration at 20 μL min−1 for 15 s. Chip
regeneration following sample injection was achieved via the
addition of sodium hydroxide solution (25 mM–50 mM) at
20 μL min−1 for 15 s. Sensorgrams obtained illustrate binding
responses in absolute RU. Data presented as response relative
to baseline is the difference in RU 10 s prior to and 30 s after
sample addition.
Fluorescence-linked immunosorbent assay (FLISA)
Human DLL4 Protein (Fc Tag) (Sino Biological) was immobi-
lized on a high-binding black plate (Greiner Bio-One) at 0.5 μg
ml−1 in PBS and left overnight. The plate was washed three
times in 0.1% PBST to remove unbound DLL4-Fc and blocked
for 1 h in 1% BSA in PBS. Following this, 0.1% PBST washes
were conducted as before, rhodamine loaded NP sample
added and left for 2 h at room temperature. Again, the plate
was washed to remove unbound NP before the addition of
acetonitrile : DMSO (1 : 1) to lyse the NPs and subsequent
assessment of binding via fluorescence (526/555).
Cell-line culture
Human umbilical vein endothelial cells (HUVEC) and normal
human lung fibroblasts (NHLF) were purchased from Lonza
and were maintained in the EGM-2 and FGM-2 bullet kits
respectively. Human Umbilical Vein Endothelial Cells
(HUVEC) were also obtained from Caltag Medsystems and cul-
tured in Human Large Vessel Endothelial Cell Growth Medium
Package (Caltag Medsystems) or endothelial cell growth
medium (ECGM) consisting of low glucose DMEM : F12 with
1% penicillin/streptomycin, 1% nonessential amino acids,
2 mM sodium pyruvate, buffered with 20 mM HEPES and con-
taining 20% FCS (Gibco), 20 μg ml−1 Heparin (Sigma), and
75 μg ml−1 endothelial mitogens (Merck). MIA PaCa-2 and
PANC-1 cells were acquired from ATCC and cultured in high
glucose DMEM supplemented with 10% FCS, 1% sodium pyru-
vate and 1% penicillin/streptomycin.
Cell lysis and BCA assay
Cells from 90 mm culture dishes were detached by scraping in
200 µL ice-cold PBS, then pelleted by centrifugation and resus-
pended in 100 µL RIPA lysis buffer supplemented with pro-
tease inhibitor cocktail tablet (Roche, UK, 1 tablet per 50 mL
buffer). The cell suspension was kept on ice for 30 min and
vortexed at regular intervals before centrifugation at 20 000g
for 10 min at 4 °C. On the completion of the centrifugation
the whole cell lysate was retrieved from the supernatant and
protein content quantified by bicinchoninic acid (BCA) assay
(Pierce, UK).
SDS-PAGE and western blotting
Lysates were denatured in X5 Laemmli Buffer at 95 °C for
10 min before separation by SDS-PAGE (8%). On the com-
pletion of protein separation proteins were transferred onto a
polyvinylidene fluoride membrane (Millipore, UK) by semi-dry
blotting. The membrane was subsequently blocked (5% w/v
milk in TBS-Tween) for, at least, 1 h.
For VEGF/FGF stimulated HUVECs under hyperoxic con-
ditions. Primary antibodies were added overnight at 4 °C.
Primary antibodies used were rat anti-α-tubulin (1 : 10 000)
(ab6160, Abcam, UK) and rat anti-human/mouse DLL4 (1 : 500)
(mab1389, R&D systems). Following primary antibody incu-
bation the membrane was washed in TBS-T and incubated
with the appropriate secondary, rabbit anti-rat HRP conjugate
(1 : 40 000) (ab102199, Abcam, UK), for 1 h. The membrane
was washed using TBS-T, before addition of chemiluminescent
substrate for 5 min and imaging of bands using a BioRad
Molecular Imager ChemiDoc XRS+ Imaging System (BioRad,
USA).
For HUVECs cultured in physiological oxygen tensions. Anti-
DLL4 primary was 2589 (Cell Signalling Technology, 1 : 1000),
anti-β-actin primary was A2228 (Sigma-Aldrich, 1 : 5000
dilution). Post-primary antibody incubation the membrane
was washed in PBST (3 × 10 minutes) and incubated with the
appropriate HRP-conjugated secondary antibody (Cell
Signalling Technology, 1 : 2000 dilution) at room temperature
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for 1 h before further PBST washing. Western Lightning ECL
Plus substrate was added and chemiluminesence detected
(G-Box, SynGene).
Surface DLL4 detection by flow cytometry
YW26.82 (human anti-DLL4 primary antibody), was expressed
by John Steven and Laura Ferguson (Elasmogen Ltd). PE-conju-
gated goat anti-human IgG secondary antibody was obtained
from eBioScience (Thermo-Fisher Scientific).
Cells were seeded (1 × 106) in a P90 and allowed to adhere
overnight. After washing once with PBS cells were detached by
addition of 0.1% EDTA-PBS (5 mL, 37 °C, 10 minutes).
Detached cells were transferred to a 15 mL tube, cold 5%
PBS-FCS (5 mL) added and cells pelleted (200g, 5 minutes,
4 °C), from this point onwards cells and all buffers were
chilled on ice. The cell pellet was resuspended in PBS-FCS
(5 mL) and divided between 4 new 15 mL tubes. Each sample
was pelleted again and resuspended in PBS-FCS (300 µL) and
YW26.82 (1 µg, 3.3 µg mL−1 final concentration) added to the
appropriate tube and incubated (30 minutes, dark, 4 °C).
PBS-FCS (5 ml) was then added to each tube and cells were pel-
leted, this was repeated once more before cells were resus-
pended in PBS-FCS (300 µL) and secondary antibody added
(1 µg, 3.3 µg mL−1 final concentration) and incubated
(20 minutes, dark, 4 °C). Cells were pelleted and washed twice
before resuspension and fluorescence analysis with at least
10 000 events collected per sample (FL2 laser, PE-A detection
channel, BD Accuri C6).
PLGA-PEG-Mal-VNAR NP confocal microscopy
HUVEC cells were seeded at 20 000 per well on an eight-well
glass culture slide (BD Falcon) and allowed to adhere over-
night. To upregulate DLL4 expression, cells were stimulated
with FGF and VEGF for 24 h. In order to assess the uptake of
nude and VNAR-targeted NPs, cells were serum starved in
serum-free media for 3 h before treating with PLGA-PEG-Mal
NPs (0.5 mg ml−1). Cells were incubated at 4 °C for 30 min,
washed in PBS (3×) and incubated at 37 °C for a further 3 h.
On the completion of the treatment period, cells were washed
with PBS (3×), treated with acid strip buffer (50 mM glycine,
150 mM NaCl in PBS, pH 3) for 5 min, washed in PBS (3×) and
fixed with 4% w/v paraformaldehyde in PBS for 20 min.
Following further washes in PBS (3×), cells were permeabilized
with 0.5% v/v Triton X-100 in PBS for 5 min. Cells were then
washed with PBS (3×) and coverslips added post application of
Vectashield antifade mounting medium with DAPI (Vector
Laboratories). Images were captured using a Leica SP8 con-
focal microscope (Leica, UK) via a HCX PL APO 1.4–0.6NA 63×
oil immersion objective zoomed 1–4× with a 1024 × 1024
frame and 400 Hz scan speed. Fluorescent images were
attained post excitation with a UV emitting diode (405 nm)
and argon (488 nm); DPSS (561 nm); or HeNe (543 nm,
594 nm and 633 nm) lasers as required. Images presented in
the same panels were acquired using standardized settings
and parameters. Image analysis was conducted using Leica
LAS X software (Leica, UK).
Cell viability assay
Cell viability was assessed via CellTiter-Glo (CTG) assay
(Promega). HUVEC cells were seeded in 96-well plates at 1500
cells per well and allowed to adhere. HUVEC cells were stimu-
lated with VEGF/FGF 24 h post seeding. Cells were sub-
sequently treated with NP formulations (48 h after seeding) for
1 h or 10 min at 4 °C before replacement of media and incu-
bation at 37 °C. After the incubation period, CellTiter-Glo
assay was performed as per manufacturers instructions.
Luminescence was measured (Biotek Synergy 2) and viability
of treated cells expressed relative to that of control cells.
HUVEC tubulogenesis assay
10 µL of growth factor reduced Matrigel (Corning) was added
to the lower well of a 15-well tissue-culture treated
Angiogenesis µ-slide (Ibidi) and allowed to polymerise for
2 hours. 3000 HUVECs at around 70% confluency and passage
<12 were then seeded in 50 µL of treatment containing media
on top of the Matrigel disc in the upper chamber of each well.
Networks of tubes were allowed to form for 5–6 hours and
imaged via phase-contrast microscopy (EVOS, 10×).
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